Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?
Table 1
Baseline characteristics for 2,644 patients with stage IIIB/IV NSCLC treated with C/C+G or C/C+T, first-line doublet chemotherapy, by histology, SEER-Medicare Data 1997–2003.
Histology
Squamous
Nonquamous
Characteristic
Patients, (%)
757 (28.6)
1,887 (71.4)
Doublet, (%)
C/C+G
84 (11.1)
289 (15.4)
C/C+T
673 (88.9)
1,598 (84.7)
Age as of initial NSCLC diagnosis:
Mean (SD)
73 (4.6)
73 (4.7)
Median
72
73
Interquartile range
69–76
69–76
Age-group as of initial NSCLC diagnosis, (%)
65–74 years
507 (67.0)
1,196 (63.4)
75+ years
250 (33.30)
691 (36.6)
Male, (%)
520 (68.7)
1,047 (55.5)
Race, (%)
Non-Hispanic Caucasian
684 (90.4)
1,718 (91.0)
Other
73 (9.6)
169 (9.0)
Geographic region, (%)
Midwest
169 (22.3)
345 (18.3)
Northeast
157 (20.8)
393 (20.8)
South
190 (25.1)
391 (20.7)
West
241 (31.8)
758 (40.2)
Location of residence, (%)
Metropolitan
628 (83.0)
1.626 (86.2)
Other
129 (17.0)
261 (13.8)
Charlson comorbidity index, mean (sd)
0.19 (0.57)
0.18 (0.52)
Notes: C/C+G: cisplatin/carboplatin and gemcitabine; C/C+T: cisplatin/carboplatin and taxane; NSCLC: non-small cell lung cancer; SD: standard deviation; SEER: surveillance, epidemiology, and end results.
